Generics pharmaceutical company Zentiva, together with private equity investors Advent and GTCR, on Thursday announced the sale of Zentiva by Advent to GTCR.
Since acquiring Zentiva from Sanofi in 2018, Advent has worked closely with the management team to transform the business, whilst investing to expand Zentiva's portfolio of medicines and manufacturing footprint, both organically and through targeted M&A.
GTCR is a US-based private equity firm with a history of investments in the healthcare sector and domain expertise in the pharmaceutical industry.
Subject to customary regulatory approvals, the transaction is expected to close in early 2026.
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment